Latest News

New structural insights accelerate drug discovery in the ubiquitin system for cancer therapy

New structural insights accelerate drug discovery in the ubiquitin system for cancer therapy

Posted 18/10/2017

A multi-disciplinary research team from the Universities of Oxford, MRC LMB, Liverpool, Cancer Research UK and pharma (Forma Therapeutics) has performed structural studies of USP7 inhibitor-enzyme interactions, demonstrating that ubiquitin-specific proteases (USPs) are tractable drug targets for cancer and also other diseases. Professor Benedikt Kessler and Dr Adan Pinto-Fernandez from Oxford’s Target Discovery Institute were part of this study.

Professor Sir Peter Ratcliffe awarded Royal Society Buchanan Medal

Professor Sir Peter Ratcliffe awarded Royal Society Buchanan Medal

Posted 22/07/2017

The Royal Society has awarded Professor Sir Peter Ratcliffe, Director of the Target Discovery Institute at the University of Oxford and Clinical Research Director at the Francis Crick Institute, with the Buchanan Medal for his ground-breaking research on oxygen sensing and signalling pathways mediating cellular responses to low oxygen levels or 'hypoxia'.

Cancer immunotherapy with p53 antibody

Cancer immunotherapy with p53 antibody

Posted 05/05/2017

p53 is one of the most damaged genes in cancer. Because p53 stays inside the cells, it is not straightforward to identify and kill the cells with damaged p53. Now we have developed an antibody that recognises a p53 fragment presented on cancer cell surface and we show that this antibody is a promising new drug for cancer immunotherapy.

World Cancer Day 2017

World Cancer Day 2017

Posted 06/02/2017

World Cancer Day takes place on February 4 each year.  NDM researchers are trying to understand the epidemiology and potential causes of cancer, its effect on patient lives and outcomes, as well as the basic science underpinning the unregulated cell growth that is the hallmark of the disease. To mark World Cancer Day 2017, NDM has asked some of our cancer scientists about their research.

John Davis: Why we work on Alzheimer’s disease

John Davis: Why we work on Alzheimer’s disease

Posted 28/11/2016

The burden caused by Alzheimer’s disease and other dementias represents one of the biggest problems for our healthcare systems. The last medicine was approved in 2002 and today we only have symptomatic treatments. ARUK-ODDI brings together chemists, biologist, psychiatrists and neuroscientists, many of them with pharmaceutical background, aiming to accelerate the discovery of novel and effective treatments, as explained by Dr John Davis.

Graduate Study Prize Winners 2016

Graduate Study Prize Winners 2016

Posted 08/11/2016

The NDM Graduate Prize winners for 2016 are Emma Davenport, Symon Kariuki, Sarah McCuaig, Manuel Rivas and Joshua Tan. The winners were awarded a £500 prize. This year’s winners have worked across many research areas including malaria vaccine work, behavioural studies and software development.

Medicine at Oxford named world's best for sixth year running

Medicine at Oxford named world's best for sixth year running

Posted 07/10/2016

Medical and health teaching and research at Oxford University has been ranked as the world's best for the sixth year running in the Times Higher Education World University Rankings. The discipline-specific tables, released today, follow on from last week's announcement that Oxford has been ranked the top university in the world by the same publication – the first time a UK institution has been awarded the accolade.

Genetic studies reveal diversity of early human populations

Genetic studies reveal diversity of early human populations

Posted 29/09/2016

Dr George Busby, a post-doc in the Kwiatkowski group, has written a piece for 'The Conversation' about how genetics is being used to answer questions about common ancestry and migration.

Oxford ranked first among global universities

Oxford ranked first among global universities

Posted 29/09/2016

Oxford becomes the first British university ever to occupy top position in the global table, which judges the performance of 980 universities across 79 countries. Oxford’s top ranking reflects its all-round strength in contemporary research and teaching. Renowned as the oldest University in the English speaking world, modern Oxford is at the forefront of the full range of academic disciplines, including medical sciences, science and engineering, humanities and social sciences.

International scientists call for a rethink on industrial and academic drug discovery

International scientists call for a rethink on industrial and academic drug discovery

Posted 20/09/2016

A group of prominent scientists, including Daniel Ebner from the TDI,  shared their opinion in Nature Reviews Drug Discovery about ineffective academic and industrial drug discovery investments and funding structures. Parallel competitive research and development funding restricted to traditional drug discovery operating models is suggested as one major contributing factor to the exponential increase in the cost of new medicines.